| Young TIL / National Cancer Institute |
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
|
|
| Recruiting | 2 | 332 | US | Young TIL, Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda) | National Cancer Institute (NCI) | Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors | 12/24 | 12/24 | | |
NCT01319565: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... |
|
|
| Active, not recruiting | 2 | 102 | US | Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI) | National Cancer Institute (NCI) | Metastatic Melanoma, Skin Cancer | 06/25 | 06/26 | | |
NCT02133196: T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 85 | US | Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL | National Cancer Institute (NCI) | Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma | 10/25 | 10/25 | | |
NCT02621021: A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab |
|
|
| Suspended | 2 | 20 | US | Cyclophosphamide, Fludarabine, Aldesleukin, Pembrolizumab, young TIL | National Cancer Institute (NCI) | Melanoma | 06/25 | 06/26 | | |
